Evidence map›Paper›PMID 34917769›Full record

ArticleClinical mass spectrometry (Del Mar, Calif.)2019

Association of PTHrP levels in CSF with Alzheimer's disease biomarkers.

Mark M Kushnir, Wojciech Michno, Alan L Rockwood, Kaj Blennow, Frederick G Strathmann, Jörg Hanrieder

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical mass spectrometry (Del Mar, Calif.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Metals in Alzheimer's Disease.Biomedicines · 2023
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 3 countries.

Mark M KushnirARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA.
Wojciech MichnoDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Alan L RockwoodRockwood Scientific Consulting, Salt Lake City, UT, USA.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Frederick G StrathmannNMS Labs, Willow Grove, PA, USA.
Jörg HanriederDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Evaporated Coatings (United States) · USSahlgrenska University Hospital · SEScientific Consulting Group · USUniversity College London · GBUniversity of Gothenburg · SEUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParathyroid hormone-related protein (PTHrP) is involved in intracellular calcium regulation, neural cell proliferation and synaptic transmission. To date, no studies have been performed to evaluate the potential of PTHrP concentrations in cerebrospinal fluid (CSF) as a biomarker of brain pathophysiology. In this study we evaluated the association between CSF concentrations of PTHrP with the core CSF biomarkers of Alzheimer's disease (AD).

methodsPTHrP and calcium were analysed using validated mass spectrometry based methods in a set of CSF samples that tested positive (n = 45) and negative (n = 45) for the AD biomarkers, including total tau protein (T-tau), phosphorylated tau protein (P-tau) and amyloid-β 42 (Aβ42). The measured CSF concentrations of PTHrP and calcium (Ca) were evaluated for association with AD CSF biomarkers.

resultsPTHrP and Ca concentrations in CSF samples ranged between 25 and 137 pmol/L and 0.92-1.53 mmol/L, respectively. Higher concentrations of PTHrP were observed in association with increased concentrations of T-tau and P-tau in the AD and the control group; while a stronger correlation was observed in the control group (ρ = 0.6, p < 0.0001; and ρ = 0.72, p < 0.0001, for T-tau and P-tau, respectively). Negative correlation was observed between concentrations of PTHrP and Aβ42 in the AD group (ρ = 0.27, p = 0.015). A statistically significantly lower ratio Aβ42/PTHrP was observed in the AD group (p < 0.0001).

conclusionIn the current study, we observed an association of PTHrP concentrations with concentrations of clinically used CSF biomarkers of AD. Concentrations of PTHrP were positively correlated with concentrations of T-tau and P-tau, suggesting an association with neuronal secretion and function, which is reduced upon progression to AD pathology. Our data suggest potential utility of the Aβ42/PTHrP ratio in assessment of AD progression.

Indexed as

15N PTHrP, parathyroid hormone related protein containing isotopically labelled nitrogenAD, Alzheimer’s diseaseAlzheimer’s diseaseAβ42, β-AmyloidBeta-amyloidCa, calciumCNS, central nervous systemCSF, cerebrospinal fluidICP-MS, inductively coupled plasma mass spectrometryLC-MS/MS, liquid chromatography tandem mass spectrometryLP, lumbar punctureMass spectrometryMS, mass spectrometryParathyroid hormone-related proteinPhosphorylated tau proteinP-tau, phosphorylated tau proteinPTH, parathyroid hormonePTHrPPTHrP, parathyroid hormone-related proteinRIA, radioimmunoassayTau proteinT-tau, total tau protein

Identifiers

PMID34917769
PMCPMC8669458
OpenAlexW2896992055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.